National and Kapodistrian University of Athens
Συσχετισμός και αξιολόγηση βιοδεικτών οστικού μεταβολισμού μετά από θεραπευτική χορήγηση ραδιοϊσοτόπων στην οστική καρκινική νόσο
Abstract
dc:descriptionAIM: To evaluate the clinical value of two novel collagen-derived serum bone makers, type I procollagen N-terminal propeptide (PINP) and cross-linked N-telopeptide of type I collagen (NTX), together with two traditional non-collagenous ones, serum bone-specific isoenzyme of alkaline phosphatase (bALP) and serum osteocalcin (OC), in patients suffering from multiple osseous metastases from prostate and breast cancer. MATERIALS-METHODS: Twenty three patients were studied from April 2005 to June 2008. Of these, 16 were males with prostate carcinoma (median age: 69.7 years, range 41-84 years) and 7 were females with breast cancer (median age: 62.9 years, range 39-81 years). All of them suffered from painful osseous metastases and were treated with 36 intravenous injections of 186Re-HEDP overall. Patients were enrolled into the study and treated with 186Re-HEDP according to the current treatment guidelines of the European Association of Nuclear Medicine (EANM). For each patient, post-treatment data were compared with pre-treatment data (baseline). The following variables were monitored for at least 3 monts after each therapy: Serum bone turnover markers (bALP, OC, PINP and NTx), clinical status, pain mapping/scoring (PSI), bone scanning findings (with SSI and BSI estimation) and total blood count parameters. The bone marker values were correlated to pain response levels and duration of response. RESULTS: The percentile decrease of baseline NTx values, as well as the value of the pretherapeutic ratio NTx/PINP proved the strongest predictors of the degree and duration of pain response after 186Re-HEDP therapies. More specifically, the degree of pain response was strongly correlated with both the maximum percentile NTx decrease after 186Re-HEDP therapies (P = 0.015-0.025, depending on pain response cut-offs) and the values of the pretherapy NTx/PINP ratio (P = 0.013), whilst the duration of response was correlated negatively with the pretherapy NTx values (HR = 2.02, P = 0.042) and positively with the pretherapy NTx/PINP ratio (HR = 2.17-2.97, P = 0.022-0.029, depending on whether dichotomic or trichotomic cut-offs were accounted). Not such apparent correlations were found with the rest of the markers. CONCLUSIONS: According to the aforementioned findings, there is a strong rationale for the established use of a potent collagenous marker of bone resorption, such as NTx, along with a resorption / formation ratio model such as NTx/PINP, the latter being a novel ratio in bone marker bibliography. Both parameters showed clear predictive value regarding the degree and duration of response after 186Re-HEDP therapies. These findings have important implications in response prediction and patient stratification, do expand our understanding of one of the most import processes of bone turnover pathophysiology evoked by bone metastases, the uncoupling phenomenon and ultimately may affect the manner in which bone-targeted therapy, such as 186Re-HEDP treatment, is studied and applied.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zafeirakis, Athanasios
- Ζαφειράκης, Αθανάσιος
Subjects
dc:subject × 16- Οστικές μεταστάσεις
- Βιοχημικοί δείκτες οστικού μεταβολισμού
- Αναλγητικές ραδιοϊσοτοπικές θεραπείες
- Ρήνιο-186-HEPD
- Αμινοτελικό τελοπεπτίδιο του κολλαγόνου Ι
- Αμινοτελικό προπεπτίδιο του προκολλαγόνου Ι
- Bone metastases
- Bone turnover markers
- Palliative radionuclide treatment
- Rhenium-186-HEPD
- N-telopeptide of type I collagen (NTx)
- N-propeptide of type I collagen (PINP)
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23802